we are focused on the cure. Our singular focus is on cell therapy the use of genetically modified immune cells programmed to target tumors which we believe has the potential to change the way cancer is treated. Through our focused efforts and important industry and academic partnerships, we have been able to advance our industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates with the goal of treating both hematological cancers and solid tumors.
